Akari Therapeutics (AKTX) to Release Quarterly Earnings on Wednesday

Akari Therapeutics (NASDAQ:AKTX) is expected to be posting its Q1 2026 results after the market closes on Wednesday, May 20th. Analysts expect Akari Therapeutics to post earnings of ($1.33) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 19, 2026 at 7:00 AM ET.

Akari Therapeutics (NASDAQ:AKTX) last issued its quarterly earnings results on Monday, March 30th. The biopharmaceutical company reported ($2.68) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($2.65).

Akari Therapeutics Trading Up 3.1%

Shares of AKTX stock traded up $0.11 on Tuesday, hitting $3.61. The company had a trading volume of 26,300 shares, compared to its average volume of 25,173. The stock’s 50-day moving average is $5.73 and its two-hundred day moving average is $11.07. Akari Therapeutics has a twelve month low of $3.02 and a twelve month high of $56.80.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Maxim Group cut Akari Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, April 8th. HC Wainwright raised their target price on Akari Therapeutics to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, April 1st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Akari Therapeutics in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Akari Therapeutics has a consensus rating of “Hold” and an average price target of $89.00.

Institutional Investors Weigh In On Akari Therapeutics

A hedge fund recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC purchased a new position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned 5.95% of Akari Therapeutics at the end of the most recent quarter. 5.06% of the stock is owned by institutional investors.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.